These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 25953829)

  • 1. Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young.
    Østoft SH; Bagger JI; Hansen T; Hartmann B; Pedersen O; Holst JJ; Knop FK; Vilsbøll T
    Eur J Endocrinol; 2015 Aug; 173(2):205-15. PubMed ID: 25953829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
    Østoft SH
    Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects.
    Rhee NA; Østoft SH; Holst JJ; Deacon CF; Vilsbøll T; Knop FK
    Eur J Endocrinol; 2014 Sep; 171(3):353-62. PubMed ID: 24935932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects.
    Knop FK; Konings E; Timmers S; Schrauwen P; Holst JJ; Blaak EE
    Diabet Med; 2013 Oct; 30(10):1214-8. PubMed ID: 23663119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
    Rosenstock J; Foley JE; Rendell M; Landin-Olsson M; Holst JJ; Deacon CF; Rochotte E; Baron MA
    Diabetes Care; 2008 Jan; 31(1):30-5. PubMed ID: 17947341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data.
    Murai K; Katsuno T; Miyagawa J; Matsuo T; Ochi F; Tokuda M; Kusunoki Y; Miuchi M; Namba M
    Drugs R D; 2014 Dec; 14(4):301-8. PubMed ID: 25420579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial.
    Kuwata H; Iwasaki M; Shimizu S; Minami K; Maeda H; Seino S; Nakada K; Nosaka C; Murotani K; Kurose T; Seino Y; Yabe D
    Diabetologia; 2016 Mar; 59(3):453-61. PubMed ID: 26704625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.
    Vilsbøll T; Krarup T; Deacon CF; Madsbad S; Holst JJ
    Diabetes; 2001 Mar; 50(3):609-13. PubMed ID: 11246881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects.
    Hansen KB; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
    J Clin Endocrinol Metab; 2011 Feb; 96(2):447-53. PubMed ID: 21047927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postprandial responses of incretin and pancreatic hormones in non-diabetic patients with end-stage renal disease.
    Idorn T; Knop FK; Jørgensen M; Holst JJ; Hornum M; Feldt-Rasmussen B
    Nephrol Dial Transplant; 2014 Jan; 29(1):119-27. PubMed ID: 24078334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
    Cuthbertson J; Patterson S; O'Harte FP; Bell PM
    Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1.
    Sonne DP; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
    Eur J Endocrinol; 2014 Oct; 171(4):407-19. PubMed ID: 24986531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia.
    Junker AE; Gluud L; Holst JJ; Knop FK; Vilsbøll T
    J Intern Med; 2016 May; 279(5):485-93. PubMed ID: 26728692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin effect and glucagon responses to oral and intravenous glucose in patients with maturity-onset diabetes of the young--type 2 and type 3.
    Østoft SH; Bagger JI; Hansen T; Pedersen O; Holst JJ; Knop FK; Vilsbøll T
    Diabetes; 2014 Aug; 63(8):2838-44. PubMed ID: 24677712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postprandial glucose, insulin and incretin responses to different carbohydrate tolerance tests.
    Deng Y; Zhang Y; Zheng S; Hong J; Wang C; Liu T; Sun Z; Gu W; Gu Y; Shi J; Yao S; Wang W; Ning G
    J Diabetes; 2015 Nov; 7(6):820-9. PubMed ID: 25395350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes.
    Højberg PV; Vilsbøll T; Zander M; Knop FK; Krarup T; Vølund A; Holst JJ; Madsbad S
    Diabet Med; 2008 Nov; 25(11):1268-75. PubMed ID: 19046215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake.
    Ryskjaer J; Deacon CF; Carr RD; Krarup T; Madsbad S; Holst J; Vilsbøll T
    Eur J Endocrinol; 2006 Sep; 155(3):485-93. PubMed ID: 16914604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
    Forst T; Anastassiadis E; Diessel S; Löffler A; Pfützner A
    Diabetes Metab Res Rev; 2014 Oct; 30(7):582-9. PubMed ID: 24459063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.
    Knop FK; Aaboe K; Vilsbøll T; Vølund A; Holst JJ; Krarup T; Madsbad S
    Diabetes Obes Metab; 2012 Jun; 14(6):500-10. PubMed ID: 22171657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.